Enacted — Signed by the President — Jul 9, 2012
Last Action: Signed by President.
Explanation: This bill was enacted after being signed by the President on July 9, 2012.
GovTrack Insider, our Kickstarter-backed work to summarize bills in Congress, has resumed. Here’s what we’ve been up to:
Mar 26, 2012
112th Congress, 2011–2013
This bill was introduced on March 26, 2012, in a previous session of Congress, but was not enacted.
Senior Senator from Colorado
Read Text »
Last Updated: Mar 26, 2012
Length: 8 pages
A bill to provide for the expedited development and evaluation of drugs designated as breakthrough drugs.
The bill’s title was written by its sponsor.
This is the first step in the legislative process.
This is a Senate bill in the United States Congress (indicated by the “S.” in “S. 2236”). A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
The committee chair determines whether a bill will move past the committee stage.
There have been no roll call votes related to this bill.
Legislative action may be ocurring on one of these bills in lieu of or in parallel to action on this bill.
Enacted — Signed by the President
Jul 9, 2012
Reported by Committee
Last Action: May 7, 2012
Search for similar bills.
Click a format for a citation suggestion:
Civic Impulse. (2016). S. 2236 — 112th Congress: Advancing Breakthrough Therapies for Patients Act of 2012. Retrieved from https://www.govtrack.us/congress/bills/112/s2236
“S. 2236 — 112th Congress: Advancing Breakthrough Therapies for Patients Act of 2012.” www.GovTrack.us. 2012. February 12, 2016 <https://www.govtrack.us/congress/bills/112/s2236>
|title=S. 2236 (112th)
|accessdate=February 12, 2016
|author=112th Congress (2012)
|date=March 26, 2012
|quote=Advancing Breakthrough Therapies for Patients Act of 2012